Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 3/20 | 0.61 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.61 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 5/20 | 0.34 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401434 | 1.00 | SLC6A12 (0.61) | SLC6A12SLC6A11SLC6A13HSD11B1GRM2 | |
| SCHEMBL27873533 | 0.77 | — | — | |
| SCHEMBL27873534 | 0.77 | — | — | |
| SCHEMBL18585427 | 0.77 | — | — | |
| SCHEMBL18585426 | 0.77 | — | — | |
| SCHEMBL18211107 | 0.75 | SLC6A12 (0.45) | SLC6A12SLC6A11SLC6A13HSD11B1 | |
| SCHEMBL3710957 | 0.73 | HSD11B1 (0.60) | SLC6A12SLC6A11SLC6A13HSD11B1GRM2 | |
| SCHEMBL23968806 | 0.71 | SLC6A12 (0.41) | SLC6A12SLC6A11SLC6A13HSD11B1 | |
| SCHEMBL7740219 | 0.70 | SLC6A12 (0.60) | SLC6A12SLC6A11SLC6A13GRM2GRM5 | |
| SCHEMBL3109773 | 0.70 | SLC6A12 (0.60) | SLC6A12SLC6A11SLC6A13GRM2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001945-B1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES | AVENTIS PHARMA INC (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-1687642-B1 | Screening methods for combinations of biological compounds | CENTELION (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070197538-A1 | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-08-23 | — | — | US | disclosed |
| EP-1687642-A2 | ANTI-VASCULAR AND ANTI-PROLIFERATION METHODS, THERAPIES, AND COMBINATIONS EMPLOYING SPECIFIC TYROSINE KINASE INHIBITORS | CENTELION (FR) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005038465-A2 | ANTI-VASCULAR AND ANTI-PROLIFERATION METHODS, THERAPIES, AND COMBINATIONS EMPLOYING SPECIFIC TYROSINE KINASE INHIBITORS | CENTELION (FR) | 2005-04-28 | — | — | WO | disclosed |
| US-6852712-B2 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-6821962-B2 | CONTROLLING CELL DIFFERENTIATION; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMACEUTICALS INC. | 2004-11-23 | — | — | US | disclosed |
| US-6696434-B2 | CONTROLLING CELL DIFFERENTIATION, CELL PROLIFERATION | AVENTIS PHARMACEUTICALS INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030139399-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. | 2003-07-24 | — | — | US | disclosed |
| US-20030139400-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2003-07-24 | — | — | US | disclosed |
| US-20030130285-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. | 2003-07-10 | — | — | US | disclosed |
| US-6528526-B1 | Inhibition of cell proliferation and/or cell matrix production and/or cell movement (chemotaxis) and/or T cell activation and proliferation | AVENTIS PHARMACEUTICALS INC. | 2003-03-04 | — | — | US | disclosed |
| US-6482834-B2 | ANTIPROLIFERATION AGENTS; ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | AVENTIS PHARMACEUTICALS INC. | 2002-11-19 | — | — | US | disclosed |
| US-20010023250-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-09-20 | — | — | US | disclosed |
| EP-1133480-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-RECEPTOR AND/OR LCK TYROSINE KINASE INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6245760-B1 | ANTICANCER AGENTS; ANTIINFLAMMATORYA GENTS; SKIN DISORDERS | AVENTIS PHARMACEUTICALS PRODUCTS, INC | 2001-06-12 | — | — | US | disclosed |
| US-6180632-B1 | USE OF THESE COMPOUNDS FOR TREATING DISORDERS/CONDITIONS INVOLVING CELLULAR DIFFERENTIATION, PROLIFERATION, EXTRACELLULAR MATRIX PRODUCTION OR MEDIATOR RELEASE AND/OR T CELL ACTIVATION AND PROLIFERATION | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-01-30 | — | — | US | disclosed |
| WO-2000031051-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-RECEPTOR AND/OR LCK TYROSINE KINASE INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139400-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases | LCK, LTK, PTK6 | SLC6A12 4677/4885SLC6A11 4620/4885SLC6A13 4749/4885 |
| US-20030130285-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, PTK6 | SLC6A12 4677/4885SLC6A11 4620/4885SLC6A13 4749/4885 |
| US-20070197538-A1 | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors | MCL1, ABL1, TIE1 | SLC6A12 4845/4885SLC6A11 4641/4885SLC6A13 4612/4885 |
| US-20010023250-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, PTK6 | SLC6A12 4677/4885SLC6A11 4620/4885SLC6A13 4749/4885 |
| US-20030139399-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, PTK6 | SLC6A12 4677/4885SLC6A11 4620/4885SLC6A13 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.